NASDAQ$TVTX
Travere Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Travere's financial performance improved, driven by FILSPARI launch and strategic progress.
Travere Therapeutics reported a successful second quarter in 2024, marked by significant growth in FILSPARI sales and new patient start forms. The company is preparing for the potential full approval of FILSPARI in IgAN, and making strides in global expansion and advancing its pipeline programs.
- Received 521 new patient start forms for FILSPARI, marking the sixth consecutive quarter of growth.
- FILSPARI net product sales reached $27.1 million, a 37% increase over the previous quarter.
- Total revenue for the second quarter was $54.1 million, with net product sales contributing $52.2 million.
- Cash, cash equivalents, and marketable securities totaled $325.4 million as of June 30, 2024.
Headline financials
Revenue & EPS history
Travere · Revenue · Quarterly
$54.1M
Revenue by segment
Travere · $33.9M total across 2 segments · Q3 2023
- Tiopronin products$25.9M+2.0%76.3%
- FILSPARI$8.04M—23.7%
Forward guidance
Travere Therapeutics anticipates potential full approval of FILSPARI in IgAN with a PDUFA target action date of September 5, 2024, and expects the first European launch of FILSPARI by CSL Vifor soon.
Tailwinds
- Potential full approval of FILSPARI for IgAN in the U.S. with upcoming PDUFA target action date.
- Expected launch of FILSPARI in Europe by CSL Vifor.
- Milestone payment of $17.5 million expected upon conversion of CMA to full approval.
- Renalys Pharma initiated a Phase 3 clinical trial of sparsentan in Japan.
- Potential inclusion of FILSPARI into the KDIGO guidelines.
Headwinds
- Risks associated with regulatory review and approval process.
- Uncertainties related to market acceptance of FILSPARI.
- Potential delays or changes in clinical trial plans.
- Dependence on contractors for clinical drug supply and commercial manufacturing.
- Risks associated with competitive products and technological changes.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-0.6%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-0.3%
Avg return
30 days after
49%
25 / 51 earnings
Positive
+16.6%
Q3 2025
Best reaction
-16.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.8% | -5.1% | +2.8% | |
| Q4 2025 | +3.1% | +0.1% | -8.4% | |
| Q3 2025 | +16.6% | +13.7% | +19.4% | |
| Q1 2025 | +1.6% | -2.6% | -27.6% | |
| Q4 2024 | -6.8% | -10.8% | -12.9% | |
| Q3 2024 | -1.1% | -0.0% | +5.9% | |
| Q2 2024 | -5.7% | -6.7% | -0.7% | |
| Q1 2024 | +7.8% | +0.6% | +25.1% | |
| Q4 2023 | -0.6% | +0.4% | -9.2% | |
| Q3 2023 | -4.7% | -16.0% | +30.3% | |
| Q2 2023 | -6.6% | -6.7% | -10.5% | |
| Q1 2023 | +5.6% | +4.2% | +19.7% | |
| Q4 2022 | +6.9% | +6.2% | +0.0% | |
| Q3 2022 | +3.1% | +0.5% | -12.4% | |
| Q2 2022 | +16.0% | +16.2% | +13.5% | |
| Q1 2022 | -14.2% | -13.2% | -6.4% | |
| Q4 2021 | +2.9% | +2.1% | -3.3% | |
| Q3 2021 | +10.0% | +15.1% | +10.8% | |
| Q2 2021 | -2.4% | +0.5% | +52.7% | |
| Q1 2021 | -16.6% | -17.4% | -41.2% | |
| Q4 2020 | -5.3% | -12.4% | -19.0% | |
| Q3 2020 | +1.6% | +11.4% | +18.1% | |
| Q2 2020 | -1.6% | -4.1% | -4.3% | |
| Q1 2020 | +7.6% | +0.8% | -0.9% | |
| Q4 2019 | -16.7% | -10.3% | -21.4% | |
| Q3 2019 | +4.4% | +8.0% | +20.7% | |
| Q2 2019 | -11.4% | -2.7% | -34.0% | |
| Q1 2019 | -7.9% | -5.5% | -2.7% | |
| Q4 2018 | +5.6% | +4.3% | +7.7% | |
| Q3 2018 | +0.6% | +1.2% | -4.4% | |
| Q2 2018 | -4.4% | -4.2% | +2.4% | |
| Q1 2018 | -5.2% | -5.7% | +11.6% | |
| Q4 2017 | +5.4% | +5.2% | -5.8% | |
| Q3 2017 | -13.4% | -16.3% | -17.1% | |
| Q2 2017 | -0.1% | +7.6% | +15.8% | |
| Q1 2017 | -4.4% | -6.5% | -7.1% | |
| Q4 2016 | +1.5% | -0.6% | -13.2% | |
| Q3 2016 | -4.3% | -1.2% | +8.5% | |
| Q2 2016 | +1.4% | -1.9% | -13.6% | |
| Q1 2016 | +5.2% | — | — | |
| Q4 2015 | -2.8% | — | — | |
| Q3 2015 | -10.0% | — | — | |
| Q2 2015 | +13.0% | — | — | |
| Q1 2015 | +5.8% | — | — | |
| Q4 2014 | +9.5% | — | — | |
| Q3 2014 | -14.4% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | +4.9% | — | — | |
| Q4 2013 | +8.4% | — | — | |
| Q3 2013 | -5.8% | — | — | |
| Q2 2012 | -9.9% | — | — | |
| Q3 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro